{"id":"cgt003-e2f-duplex-decoy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"E2F transcription factors are key regulators of the cell cycle and are often dysregulated in cancer and fibrotic diseases. By acting as a molecular decoy, CGT003 competitively binds E2F proteins and prevents them from activating their target genes, thereby inhibiting aberrant cell proliferation. This mechanism is intended to reduce pathological cell growth in conditions driven by E2F overactivity.","oneSentence":"CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:27.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT00042081","phase":"PHASE3","title":"Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures","status":"COMPLETED","sponsor":"Anesiva, Inc.","startDate":"2002-07","conditions":"Coronary Artery Disease","enrollment":3000},{"nctId":"NCT00041925","phase":"PHASE2, PHASE3","title":"Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures","status":"COMPLETED","sponsor":"Anesiva, Inc.","startDate":"2001-11","conditions":"Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CGT003 (E2F Duplex Decoy)","genericName":"CGT003 (E2F Duplex Decoy)","companyName":"Anesiva, Inc.","companyId":"anesiva-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival. Used for Solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}